Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 1
Submit an article Journal homepage
487
Views
27
CrossRef citations to date
0
Altmetric
Original Article

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation

John J.P. Kastelein Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsCorrespondence[email protected]
,
Raphaël Duivenvoorden Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
John Deanfield Cardiothoracic Unit, Great Ormond Street Hospital, London, UK
,
Eric de Groot Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
J. Wouter Jukema Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
,
Juan-Carlos Kaski Department of Cardiovascular Sciences, St George's University of London, London, UK
,
Thomas Münzel Department of Medicine II, Johannes Gutenberg-University Mainz, Mainz, Germany
,
Stefano Taddei Hypertension Service, Università di Pisa, Pisa, Italy
,
Valerie Lehnert F. Hoffmann-La Roche Ltd, Basel, Switzerland
,
Tracy Burgess F. Hoffmann-La Roche Inc., Nutley, NJ, USA
,
David Kallend F. Hoffmann-La Roche Ltd, Basel, Switzerland
&
Thomas F. Lüscher Cardiovascular Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
 show all
Pages 141-150 | Accepted 27 Oct 2010, Published online: 06 Dec 2010

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sheila A Doggrell. (2012) Dalcetrapib – restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease. Expert Opinion on Investigational Drugs 21:4, pages 569-573.
Read now
Olaf Kuhlmann & Katja Heinig. (2011) Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica 41:5, pages 430-436.
Read now

Articles from other publishers (25)

Han Xue, Meng Zhang, Jianfang Liu, Jianjun Wang & Gang Ren. (2023) Structure-based mechanism and inhibition of cholesteryl ester transfer protein. Current Atherosclerosis Reports 25:4, pages 155-166.
Crossref
Natalie C. Ward, Wann Jia Loh & Gerald F. Watts. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus 357 406 .
Surojit Banerjee & Abhijit De. (2021) Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update. Drug Discovery Today 26:7, pages 1759-1764.
Crossref
Eric de Groot, Lisa Schweitzer & Stephan Theis. (2020) Efficacy of Isomaltulose Compared to Sucrose in Modulating Endothelial Function in Overweight Adults. Nutrients 12:1, pages 141.
Crossref
A. Ali & J. Duffy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 284 307 .
Anouar Hafiane & Jacques Genest. (2015) High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clinical 3, pages 175-188.
Crossref
Sandra J. Hamilton & Gerald F. Watts. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus 239 278 .
Marietta Charakida, Eric de Groot, Stavros P. Loukogeorgakis, Tauseef Khan, Thomas Lüscher, John J. Kastelein, Theo Gasser & John E. Deanfield. (2013) Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. European Heart Journal 34:45, pages 3501-3507.
Crossref
Robert S. RosensonH. Bryan BrewerJrJrBenjamin AnsellPhilip BarterM. John ChapmanJay W. HeineckeAnatol KontushAlan R. TallNancy R. Webb. (2013) Translation of High-Density Lipoprotein Function Into Clinical Practice. Circulation 128:11, pages 1256-1267.
Crossref
Raphaël Duivenvoorden & Zahi A. Fayad. (2012) Safety of CETP inhibition. Current Opinion in Lipidology 23:6, pages 518-524.
Crossref
Pamela M. Katz & Lawrence A. Leiter. (2012) Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology 28:6, pages 667-677.
Crossref
David RhaindsBenoit J ArsenaultMathieu R BrodeurJean-Claude Tardif. (2012) An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiology 8:4, pages 513-531.
Crossref
Thomas F. Lüscher, Stefano Taddei, Juan-Carlos Kaski, J. Wouter Jukema, David Kallend, Thomas Münzel, John J.P. Kastelein & John E. Deanfield. (2012) Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. European Heart Journal 33:7, pages 857-865.
Crossref
Valerie Cheung & Robert A. Hegele. (2011) CETP Inhibitors: Will They Live up to Their Promise?. Current Cardiovascular Risk Reports 6:1, pages 4-11.
Crossref
Gregory G. Schwartz. (2011) New Horizons for Cholesterol Ester Transfer Protein Inhibitors. Current Atherosclerosis Reports 14:1, pages 41-48.
Crossref
S. BIERE‐RAFI, A. TUINENBURG, B.W. HAAK, M. PETERS, R. HUIJGEN, E. de GROOT, P. VERHAMME, K. PEERLINCK, F.L.J. VISSEREN, M.J.H.A. KRUIP, B.A.P. LAROS‐van GORKOM, V.E.A. GERDES, H.R. BULLER, R.E.G. SCHUTGENS & P.W. KAMPHUISEN. (2012) Factor VIII deficiency does not protect against atherosclerosis. Journal of Thrombosis and Haemostasis 10:1, pages 30-37.
Crossref
Ragavendra R. Baliga. (2012) HDL–Cholesterol: Perfection is the Enemy of Good?. Medical Clinics of North America 96:1, pages 27-37.
Crossref
Wael ElMallah & Richard A. Krasuski. (2011) Therapy and clinical trials. Current Opinion in Lipidology 22:6, pages 512-513.
Crossref
Philip Barter & Kerry-Anne Rye. (2011) Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. Trends in Pharmacological Sciences 32:12, pages 694-699.
Crossref
Peter P. Toth. (2011) CETP Inhibition: Does the Future Look Promising?. Current Cardiology Reports 13:6, pages 559-565.
Crossref
Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt, Tracy Burgess, Valentin Fuster, Christie M Ballantyne, Evan A Stein, Jean-Claude Tardif, James H F Rudd, Michael E Farkouh & Ahmed Tawakol. (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. The Lancet 378:9802, pages 1547-1559.
Crossref
Zahi A. Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Sameer Bansilal, Joseph Pozza, Tracy Burgess, Valentin Fuster, James H.F. Rudd, Ahmed Tawakol & Michael E. Farkouh. (2011) Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. American Heart Journal 162:2, pages 214-221.e2.
Crossref
Cameron J. Smith, Amjad Ali, Milton L. Hammond, Hong Li, Zhijian Lu, Joann Napolitano, Gayle E. Taylor, Christopher F. Thompson, Matt S. Anderson, Ying Chen, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Carl P. Sparrow, Samuel D. Wright, Anne-Marie Cumiskey, Melanie Latham, Laurence B. Peterson, Ray Rosa, James V. Pivnichny, Xinchun Tong, Suoyu S. Xu & Peter J. Sinclair. (2011) Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib. Journal of Medicinal Chemistry 54:13, pages 4880-4895.
Crossref
Raphaël Duivenvoorden & Zahi A. Fayad. (2011) Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein–Raising Therapies. Current Atherosclerosis Reports 13:3, pages 277-284.
Crossref
Elizabeth A. Ellins & Julian P. J. Halcox. (2011) Where Are We Heading with Noninvasive Clinical Vascular Physiology? Why and How Should We Assess Endothelial Function?. Cardiology Research and Practice 2011, pages 1-9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.